These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19966867)

  • 1. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.
    Kim YH; Kwei KA; Girard L; Salari K; Kao J; Pacyna-Gengelbach M; Wang P; Hernandez-Boussard T; Gazdar AF; Petersen I; Minna JD; Pollack JR
    Oncogene; 2010 Mar; 29(10):1421-30. PubMed ID: 19966867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
    Cheung HW; Du J; Boehm JS; He F; Weir BA; Wang X; Butaney M; Sequist LV; Luo B; Engelman JA; Root DE; Meyerson M; Golub TR; Jänne PA; Hahn WC
    Cancer Discov; 2011 Dec; 1(7):608-25. PubMed ID: 22586683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer.
    Natsume H; Shinmura K; Tao H; Igarashi H; Suzuki M; Nagura K; Goto M; Yamada H; Maeda M; Konno H; Nakamura S; Sugimura H
    J Transl Med; 2012 Jul; 10():97. PubMed ID: 22591714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent amplification in the 22q11 region in laryngeal squamous cell carcinoma results in overexpression of the CRKL but not the MAPK1 oncogene.
    Kostrzewska-Poczekaj M; Giefing M; Jarmuz M; Brauze D; Pelinska K; Grenman R; Bartochowska A; Szyfter W; Szyfter K
    Cancer Biomark; 2010-2011; 8(1):11-9. PubMed ID: 21896986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer.
    Wang Y; Dong QZ; Fu L; Stoecker M; Wang E; Wang EH
    Mol Carcinog; 2013 Nov; 52(11):890-9. PubMed ID: 22753141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal amplification and oncogene dependency of GAB2 in breast cancer.
    Bocanegra M; Bergamaschi A; Kim YH; Miller MA; Rajput AB; Kao J; Langerød A; Han W; Noh DY; Jeffrey SS; Huntsman DG; Børresen-Dale AL; Pollack JR
    Oncogene; 2010 Feb; 29(5):774-9. PubMed ID: 19881546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer.
    Kwei KA; Kim YH; Girard L; Kao J; Pacyna-Gengelbach M; Salari K; Lee J; Choi YL; Sato M; Wang P; Hernandez-Boussard T; Gazdar AF; Petersen I; Minna JD; Pollack JR
    Oncogene; 2008 Jun; 27(25):3635-40. PubMed ID: 18212743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.
    An R; Wang Y; Voeller D; Gower A; Kim IK; Zhang YW; Giaccone G
    Oncotarget; 2016 May; 7(20):29199-210. PubMed ID: 27078848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
    Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
    Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRKL promotes lung cancer cell invasion through ERK-MMP9 pathway.
    Lin F; Chengyao X; Qingchang L; Qianze D; Enhua W; Yan W
    Mol Carcinog; 2015 Jun; 54 Suppl 1():E35-44. PubMed ID: 24664993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.
    Yanagi H; Wang L; Nishihara H; Kimura T; Tanino M; Yanagi T; Fukuda S; Tanaka S
    Biochem Biophys Res Commun; 2012 Feb; 418(1):104-9. PubMed ID: 22244889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy number gains of the putative CRKL oncogene in laryngeal squamous cell carcinoma result in strong nuclear expression of the protein and influence cell proliferation and migration.
    Kostrzewska-Poczekaj M; Bednarek K; Jarmuz-Szymczak M; Bodnar M; Filas V; Marszalek A; Bartochowska A; Grenman R; Kiwerska K; Szyfter K; Giefing M
    Sci Rep; 2020 Jan; 10(1):24. PubMed ID: 31913340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
    Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
    J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.
    Lorenzetto E; Brenca M; Boeri M; Verri C; Piccinin E; Gasparini P; Facchinetti F; Rossi S; Salvatore G; Massimino M; Sozzi G; Maestro R; Modena P
    Oncotarget; 2014 May; 5(9):2608-21. PubMed ID: 24810989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.
    Lockwood WW; Chari R; Coe BP; Thu KL; Garnis C; Malloff CA; Campbell J; Williams AC; Hwang D; Zhu CQ; Buys TP; Yee J; English JC; Macaulay C; Tsao MS; Gazdar AF; Minna JD; Lam S; Lam WL
    PLoS Med; 2010 Jul; 7(7):e1000315. PubMed ID: 20668658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.
    Castillo SD; Angulo B; Suarez-Gauthier A; Melchor L; Medina PP; Sanchez-Verde L; Torres-Lanzas J; Pita G; Benitez J; Sanchez-Cespedes M
    J Pathol; 2010 Sep; 222(1):89-98. PubMed ID: 20556744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer.
    Kwei KA; Bashyam MD; Kao J; Ratheesh R; Reddy EC; Kim YH; Montgomery K; Giacomini CP; Choi YL; Chatterjee S; Karikari CA; Salari K; Wang P; Hernandez-Boussard T; Swarnalata G; van de Rijn M; Maitra A; Pollack JR
    PLoS Genet; 2008 May; 4(5):e1000081. PubMed ID: 18535672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas.
    Lin L; Miller CT; Contreras JI; Prescott MS; Dagenais SL; Wu R; Yee J; Orringer MB; Misek DE; Hanash SM; Glover TW; Beer DG
    Cancer Res; 2002 Sep; 62(18):5273-9. PubMed ID: 12234996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
    Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
    Hemmeryckx B; van Wijk A; Reichert A; Kaartinen V; de Jong R; Pattengale PK; Gonzalez-Gomez I; Groffen J; Heisterkamp N
    Cancer Res; 2001 Feb; 61(4):1398-405. PubMed ID: 11245441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.